<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="ccr39220" xml:lang="en" article-type="case-study"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">Clin Case Rep</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2050-0904</journal-id><journal-id journal-id-type="publisher-id">CCR3</journal-id><journal-title-group><journal-title>Clinical Case Reports</journal-title></journal-title-group><issn pub-type="epub">2050-0904</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11785468</article-id><article-id pub-id-type="doi">10.1002/ccr3.9220</article-id><article-id pub-id-type="publisher-id">CCR39220</article-id><article-id pub-id-type="other">CCR3-2024-04-1172.R1</article-id><article-categories><subj-group subj-group-type="article-subject-classification"><subject>General Medicine</subject></subj-group><subj-group subj-group-type="article-subject-classification"><subject>Oncology</subject></subj-group><subj-group subj-group-type="article-subject-classification"><subject>Nephrology</subject></subj-group><subj-group subj-group-type="overline"><subject>Case Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Renal cell carcinoma presents as portal vein thrombosis, a very rare combination</article-title><alt-title alt-title-type="left-running-head">Alhaj Tahtouh et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="ccr39220-cr-0001" contrib-type="author" corresp="yes"><name><surname>Alhaj Tahtouh</surname><given-names>Raad</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-3077-962X</contrib-id><xref rid="ccr39220-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>raadtah@gmail.com</email></address></contrib><contrib id="ccr39220-cr-0002" contrib-type="author"><name><surname>Sawan</surname><given-names>Raidah</given-names></name><xref rid="ccr39220-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ccr39220-cr-0003" contrib-type="author"><name><surname>Alwassiti</surname><given-names>Wisam</given-names></name><xref rid="ccr39220-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ccr39220-cr-0004" contrib-type="author"><name><surname>Ali</surname><given-names>Ahmad</given-names></name><xref rid="ccr39220-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ccr39220-cr-0005" contrib-type="author"><name><surname>Alkhodari</surname><given-names>Khaled</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0437-8003</contrib-id><xref rid="ccr39220-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ccr39220-cr-0006" contrib-type="author"><name><surname>Azhar</surname><given-names>Khalid</given-names></name><xref rid="ccr39220-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="ccr39220-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Internal Medicine Department</named-content>
<institution>Hamad Medical Corporation (HMC)</institution>
<city>Doha</city>
<country country="QA">Qatar</country>
</aff><aff id="ccr39220-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Internal Medicine Department</named-content>
<institution>Damascus University</institution>
<city>Damascus</city>
<country country="SY">Syria</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Raad Alhaj Tahtouh, 2212 Deer Lakes Dr, Amherst, Buffalo, NY, USA.<break/>
Email: <email>raadtah@gmail.com</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue seq="390">2</issue><issue-id pub-id-type="doi">10.1002/ccr3.v13.2</issue-id><elocation-id>e9220</elocation-id><history>
<date date-type="rev-recd"><day>19</day><month>5</month><year>2024</year></date>
<date date-type="received"><day>28</day><month>4</month><year>2024</year></date>
<date date-type="accepted"><day>22</day><month>6</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Clinical Case Reports</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CCR3-13-e9220.pdf"/><abstract><sec id="ccr39220-sec-0001"><title>Key Clinical Message</title><p>Portal vein thrombosis (PVT) can indicate underlying conditions, such as malignancy. A case of PVT was later diagnosed as renal cell carcinoma (RCC), highlighting the need to consider cancer in PVT cases and ensure a comprehensive evaluation.</p></sec><sec id="ccr39220-sec-0002"><title>Abstract</title><p>Portal vein thrombosis (PVT) is a rare complication that can arise from various underlying conditions. We present a case report of a patient initially presenting with PVT, which was later diagnosed as renal cell carcinoma (RCC). This case highlights the importance of considering malignancy as a potential cause of PVT and the need for a comprehensive evaluation.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ccr39220-kwd-0001">comprehensive evaluation</kwd><kwd id="ccr39220-kwd-0002">diagnosis</kwd><kwd id="ccr39220-kwd-0003">malignancy</kwd><kwd id="ccr39220-kwd-0004">portal vein thrombosis</kwd><kwd id="ccr39220-kwd-0005">rare complication</kwd><kwd id="ccr39220-kwd-0006">renal cell carcinoma</kwd></kwd-group><counts><fig-count count="4"/><table-count count="1"/><page-count count="4"/><word-count count="1900"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.3 mode:remove_FC converted:31.01.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="CCR39220-cit-2001">
<string-name>
<surname>Alhaj Tahtouh</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sawan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Alwassiti</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Ali</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Alkhodari</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Azhar</surname>
<given-names>K</given-names>
</string-name>. <article-title>Renal cell carcinoma presents as portal vein thrombosis, a very rare combination</article-title>. <source>Clin Case Rep</source>. <year>2025</year>;<volume>13</volume>:<elocation-id>e9220</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/ccr3.9220</pub-id>
</mixed-citation>
</p></notes></front><body id="ccr39220-body-0001"><sec id="ccr39220-sec-0003"><label>1</label><title>INTRODUCTION</title><p>Renal cell carcinoma (RCC) is the most common type of kidney cancer, typically presenting symptoms related to the urinary tract or metastatic spread.<xref rid="ccr39220-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> However, RCC can occasionally manifest with atypical signs and symptoms, leading to diagnostic challenges. Portal vein thrombosis (PVT) is a rare complication of RCC,<xref rid="ccr39220-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> and its presence as the initial presentation is even rarer. In this case report, we discuss a unique case in which PVT served as the presenting sign of RCC, highlighting the importance of considering RCC in the differential diagnosis of patients with PVT.</p></sec><sec id="ccr39220-sec-0004"><label>2</label><title>CASE HISTORY/EXAMINATION</title><p>A 50&#x02010;year&#x02010;old female patient presented to the emergency department with a chief complaint of epigastric pain lasting for 5&#x02009;days. The pain began gradually and was rated as 5 out of 10 in intensity. It was constant and did not radiate to the back or shoulder. The patient reported experiencing associated nausea but no vomiting, abdominal distension, diarrhea, or constipation. Furthermore, the patient denied any dysuria, frequency, or oliguria history. There were no signs of fever, weight loss, or anorexia. Additionally, there was no evidence to suggest any connective tissue diseases in the patient's medical history. Notably, the patient had a previous medical history of a left breast fibroadenoma surgically removed 10&#x02009;years ago. There was no history of smoking or alcohol consumption and no history of cirrhosis. The patient was not taking any medications at home.</p><p>A physical examination revealed no significant abnormalities except mild tenderness in the epigastric region.</p></sec><sec id="ccr39220-sec-0005"><label>3</label><title>METHODS (DIFFERENTIAL DIAGNOSIS, INVESTIGATIONS, AND TREATMENT)</title><p>The patient underwent basic blood tests and imaging studies to further investigate her condition. A CT scan of the abdomen with contrast (refer to Figures&#x000a0;<xref rid="ccr39220-fig-0001" ref-type="fig">1</xref> and <xref rid="ccr39220-fig-0002" ref-type="fig">2</xref>) revealed the presence of left portal vein thrombosis and a complex cystic lesion in the right kidney. To explore potential causes of portal vein thrombosis, additional investigations were conducted to rule out thrombophilia syndromes and autoimmune diseases, and the results were negative (refer to Table&#x000a0;<xref rid="ccr39220-tbl-0001" ref-type="table">1</xref>). Subsequently, the patient was initiated on anticoagulation therapy.</p><fig position="float" fig-type="FIGURE" id="ccr39220-fig-0001"><label>FIGURE 1</label><caption><p>A CT scan of the abdomen with contrast showing a right renal complex cystic lesion.</p></caption><graphic xlink:href="CCR3-13-e9220-g003" position="anchor" id="jats-graphic-1"/></fig><fig position="float" fig-type="FIGURE" id="ccr39220-fig-0002"><label>FIGURE 2</label><caption><p>A CT scan of the abdomen with contrast showing portal vein thrombosis.</p></caption><graphic xlink:href="CCR3-13-e9220-g001" position="anchor" id="jats-graphic-3"/></fig><table-wrap position="float" id="ccr39220-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Descriptions of common blood tests including coagulation profile.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Laboratory test</th><th align="left" valign="bottom" rowspan="1" colspan="1">Result</th><th align="left" valign="bottom" rowspan="1" colspan="1">Normal value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">White blood cell count</td><td align="left" valign="top" rowspan="1" colspan="1">7&#x02009;&#x000d7;&#x02009;10<sup>3</sup>/&#x003bc;L</td><td align="left" valign="top" rowspan="1" colspan="1">(4&#x02013;10)&#x02009;&#x000d7;&#x02009;10<sup>3</sup>/&#x003bc;L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hemoglobulin</td><td align="left" valign="top" rowspan="1" colspan="1">13.2&#x02009;g/dL</td><td align="left" valign="top" rowspan="1" colspan="1">(13&#x02013;17)&#x02009;g/dL</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Platelet</td><td align="left" valign="top" rowspan="1" colspan="1">342&#x02009;&#x000d7;&#x02009;10<sup>3</sup>/&#x003bc;L</td><td align="left" valign="top" rowspan="1" colspan="1">(150&#x02013;400)&#x02009;&#x000d7;&#x02009;10<sup>3</sup>/&#x003bc;L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Urea</td><td align="left" valign="top" rowspan="1" colspan="1">4.2&#x02009;mmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">(3.2&#x02013;7.4)&#x02009;mmol/L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine</td><td align="left" valign="top" rowspan="1" colspan="1">61&#x02009;umol/L</td><td align="left" valign="top" rowspan="1" colspan="1">(64&#x02013;110)&#x02009;umol/L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1C %</td><td align="left" valign="top" rowspan="1" colspan="1">5.8%</td><td align="left" valign="top" rowspan="1" colspan="1">4.8%&#x02013;5.9%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">C&#x02010;reactive protein</td><td align="left" valign="top" rowspan="1" colspan="1">63&#x02009;mg/L</td><td align="left" valign="top" rowspan="1" colspan="1">(0&#x02013;5)&#x02009;mg/L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alanine aminotransferase</td><td align="left" valign="top" rowspan="1" colspan="1">60&#x02009;U/L</td><td align="left" valign="top" rowspan="1" colspan="1">(0&#x02013;41&#x02009;U/L)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aspartate aminotransferase</td><td align="left" valign="top" rowspan="1" colspan="1">38&#x02009;U/L</td><td align="left" valign="top" rowspan="1" colspan="1">(0&#x02013;40&#x02009;U/L)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alkaline phosphatase</td><td align="left" valign="top" rowspan="1" colspan="1">95&#x02009;U/L</td><td align="left" valign="top" rowspan="1" colspan="1">(40&#x02013;129&#x02009;U/L)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">D&#x02010;Dimer</td><td align="left" valign="top" rowspan="1" colspan="1">0.43&#x02009;mg/L</td><td align="left" valign="top" rowspan="1" colspan="1">0.49&#x02013;0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Prothrombin time</td><td align="left" valign="top" rowspan="1" colspan="1">10.0&#x02009;s</td><td align="left" valign="top" rowspan="1" colspan="1">11.8&#x02013;9.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">INR</td><td align="left" valign="top" rowspan="1" colspan="1">0.9</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APTT</td><td align="left" valign="top" rowspan="1" colspan="1">27.1&#x02009;s</td><td align="left" valign="top" rowspan="1" colspan="1">31.2&#x02013;24.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fibrinogen</td><td align="left" valign="top" rowspan="1" colspan="1">5.83&#x02009;g/L</td><td align="left" valign="top" rowspan="1" colspan="1">4.20&#x02013;1.70</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Protein S activity</td><td align="left" valign="top" rowspan="1" colspan="1">106.0%</td><td align="left" valign="top" rowspan="1" colspan="1">126.0%&#x02013;56.1%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Protein C activity</td><td align="left" valign="top" rowspan="1" colspan="1">134.7%</td><td align="left" valign="top" rowspan="1" colspan="1">70%&#x02013;140%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Antithrombin activity</td><td align="left" valign="top" rowspan="1" colspan="1">93.7%</td><td align="left" valign="top" rowspan="1" colspan="1">112.0%&#x02013;79.4%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Homocysteine plasma</td><td align="left" valign="top" rowspan="1" colspan="1">10.4&#x02009;umol/L</td><td align="left" valign="top" rowspan="1" colspan="1">0.0&#x02013;15.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Factor v laden</td><td align="left" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ANA CTD</td><td align="left" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rheumatoid factor</td><td align="left" valign="top" rowspan="1" colspan="1">10&#x02009;IU/mL</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x02013;14&#x02009;IU/mL</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anticardiolipin Ab IgG</td><td align="left" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anticardiolipin Ab IgM</td><td align="left" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti B2 glycoprotein IgG</td><td align="left" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti B2 glycoprotein IgM</td><td align="left" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lupus anticoagulant</td><td align="left" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>An MRI scan of the abdomen with contrast was then performed, and the results indicated that the renal cyst exhibited MRI features consistent with renal cell carcinoma (refer to Figures&#x000a0;<xref rid="ccr39220-fig-0003" ref-type="fig">3</xref> and <xref rid="ccr39220-fig-0004" ref-type="fig">4</xref>). Consequently, the portal vein thrombosis was considered secondary to a possible renal cell carcinoma.</p><fig position="float" fig-type="FIGURE" id="ccr39220-fig-0003"><label>FIGURE 3</label><caption><p>MRI scan of the abdomen showing the left renal vein thrombosis.</p></caption><graphic xlink:href="CCR3-13-e9220-g004" position="anchor" id="jats-graphic-5"/></fig><fig position="float" fig-type="FIGURE" id="ccr39220-fig-0004"><label>FIGURE 4</label><caption><p>MRI scan of the abdomen with contrast showing right renal mass suggestive of renal cell carcinoma.</p></caption><graphic xlink:href="CCR3-13-e9220-g002" position="anchor" id="jats-graphic-7"/></fig></sec><sec id="ccr39220-sec-0006"><label>4</label><title>CONCLUSION AND RESULTS (OUTCOME AND FOLLOW&#x02010;UP)</title><p>The patient was discharged with a prescription for rivaroxaban and scheduled for a follow&#x02010;up with the uro&#x02010;oncology team. Although a partial nephrectomy was initially offered as a treatment option, the patient expressed reluctance toward surgery and opted for active surveillance. However, later on, the patient traveled to the United States, where she underwent a robotic&#x02010;assisted partial nephrectomy. A tissue biopsy subsequently confirmed the presence of clear&#x02010;cell renal cell carcinoma.</p></sec><sec sec-type="discussion" id="ccr39220-sec-0007"><label>5</label><title>DISCUSSION</title><p>We are reporting a case of RCC presented with portal vein thrombosis.</p><p>Portal vein thrombosis is a relatively rare condition that can occur due to various etiologies, including cirrhosis, hypercoagulable states, infection, and malignancy. RCC&#x02010;associated PVT is an uncommon phenomenon, accounting for approximately 4%&#x02013;10% of cases.<xref rid="ccr39220-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> However, it is crucial to consider malignancies, especially RCC, as an underlying cause, even in the absence of typical risk factors. RCC is known to exhibit unique characteristics such as tumor thrombus formation, which can extend into the renal vein, inferior vena cava, and even the hepatic veins.<xref rid="ccr39220-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>The mechanism behind PVT development in RCC involves the tumor's direct invasion into the renal vein, subsequently propagating into the portal vein. The underlying mechanisms that promote thrombosis in RCC remain poorly understood but are likely multifactorial, involving tumor&#x02010;derived procoagulant factors, platelet activation, and endothelial dysfunction.<xref rid="ccr39220-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><p>In this case, the patient's initial abdominal pain symptoms and the presence of PVT raised suspicion for an underlying liver pathology. However, the subsequent imaging studies, particularly the contrast&#x02010;enhanced CT scan, identified renal mass as the primary cause. It is important to note that RCC&#x02010;associated PVT can present with nonspecific symptoms, which may mimic other etiologies, further complicating the diagnosis.</p><p>The diagnosis of RCC as the underlying cause of PVT can be challenging due to the lack of specific symptoms and the rarity of this presentation. Patients with RCC&#x02010;associated PVT often present with nonspecific symptoms related to the liver and the gastrointestinal tract.<xref rid="ccr39220-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> These symptoms may mimic other conditions such as liver cirrhosis, hepatocellular carcinoma, or gastrointestinal malignancies. Consequently, the diagnosis of RCC can be delayed, leading to a poorer prognosis. Therefore, it is crucial to consider RCC as a potential cause in patients presenting with PVT, especially when there are no other evident etiologies.</p><p>Imaging studies play a vital role in diagnosing RCC&#x02010;associated PVT. Abdominal ultrasound, CT scan, and magnetic resonance imaging (MRI) can detect both the renal mass and the thrombus within the portal vein. These imaging modalities help determine the extent of the thrombus, assess the involvement of adjacent structures, and aid in surgical planning.<xref rid="ccr39220-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>The management of RCC&#x02010;associated PVT typically involves a multidisciplinary approach. Surgical resection remains the gold standard treatment for localized RCC, often including removing the tumor thrombus.<xref rid="ccr39220-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Systemic therapy with targeted agents or immunotherapy may be considered in cases of metastatic disease or unresectable tumors. Anticoagulation therapy may also be initiated to prevent further clot propagation and manage thrombotic complications.</p><p>Prognosis in cases of RCC&#x02010;associated PVT depends on several factors, including the stage of the tumor, the presence of distant metastasis, and the response to treatment. Generally, patients with localized disease and an early diagnosis have a better prognosis compared to those with advanced disease. However, the presence of PVT itself is considered a poor prognostic factor, highlighting the need for prompt recognition and treatment.<xref rid="ccr39220-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>Our case is the first case reported as localized RCC with concomitant PVT without other thrombotic events or risk factors. It is interesting as portal thrombosis rarely presents as the initial clue of RCC in the absence of any other risk factor, in almost all cases, the RCC is discovered first or recurrence of RCC after nephrectomy in the cause.<xref rid="ccr39220-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> It is reasonable as well to look for PVT as one of the complications or paraneoplastic syndromes in RCC patients.</p></sec><sec sec-type="conclusions" id="ccr39220-sec-0008"><label>6</label><title>CONCLUSION</title><p>This case report underscores the importance of considering malignancy, particularly renal cell carcinoma, as an underlying cause of portal vein thrombosis. Clinicians should maintain a high index of suspicion for RCC when evaluating patients presenting with PVT, especially in the absence of typical risk factors. Prompt diagnosis and appropriate management are essential to improve patient outcomes and prevent further complications associated with RCC and PVT.</p></sec><sec id="ccr39220-sec-0014"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Raad Alhaj Tahtouh:</bold> Formal analysis; supervision; writing &#x02013; original draft. <bold>Wisam Alwassiti:</bold> Formal analysis; writing &#x02013; original draft; writing &#x02013; review and editing. <bold>Raidah Sawan:</bold> Investigation; writing &#x02013; original draft; writing &#x02013; review and editing. <bold>Ahmad Ali:</bold> Investigation; writing &#x02013; original draft; writing &#x02013; review and editing. <bold>Khaled Alkhodari:</bold> Formal analysis; supervision. <bold>Khalid Azhar:</bold> Investigation; resources; supervision.</p></sec><sec id="ccr39220-sec-0010"><title>FUNDING INFORMATION</title><p>Abhath funded this case report at Hamad Medical Corporation.</p></sec><sec sec-type="conclusions" id="ccr39220-sec-0013"><title>CONSENT</title><p>Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy.</p></sec></body><back><ack id="ccr39220-sec-0009"><title>ACKNOWLEDGMENTS</title><p>We extend our gratitude to the patient for consenting to the publication of this case. We also wish to acknowledge the contributions of our colleagues and the medical staff, who played a critical role in the diagnosis and treatment. Their expertise and commitment were essential in handling this rare case. Hamad Medical Corporation Open Access publishing facilitated by the Qatar National Library, as part of the Wiley Qatar National Library agreement.</p></ack><sec sec-type="data-availability" id="ccr39220-sec-0012"><title>DATA AVAILABILITY STATEMENT</title><p>Data are openly available in a public repository that issues datasets with DOIs.</p></sec><ref-list content-type="cited-references" id="ccr39220-bibl-0001"><title>REFERENCES</title><ref id="ccr39220-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="ccr39220-cit-0001">
<article-title>Kidney Cancer: Symptoms, Signs, Causes &#x00026; Treatment</article-title>. n.d. Accessed June 8, 2023. <ext-link xlink:href="https://my.clevelandclinic.org/health/diseases/9409-kidney-cancer-overview" ext-link-type="uri">https://my.clevelandclinic.org/health/diseases/9409&#x02010;kidney&#x02010;cancer&#x02010;overview</ext-link>
</mixed-citation></ref><ref id="ccr39220-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ccr39220-cit-0002">
<string-name>
<surname>Ihaddadene</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Yokom</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Le Gal</surname>
<given-names>G</given-names>
</string-name>, et&#x000a0;al. <article-title>The risk of venous thromboembolism in renal cell carcinoma patients with residual tumor thrombus</article-title>. <source>J Thromb Hemost</source>. <year>2014</year>;<volume>12</volume>(<issue>6</issue>):<fpage>855</fpage>&#x02010;<lpage>859</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jth.12580</pub-id>
</mixed-citation></ref><ref id="ccr39220-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ccr39220-cit-0003">
<string-name>
<surname>Padala</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Barsouk</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Thandra</surname>
<given-names>KC</given-names>
</string-name>, et&#x000a0;al. <article-title>Epidemiology of renal cell carcinoma</article-title>. <source>World J Oncol</source>. <year>2020</year>;<volume>11</volume>(<issue>3</issue>):<fpage>79</fpage>&#x02010;<lpage>87</lpage>. doi:<pub-id pub-id-type="doi">10.14740/wjon1279</pub-id>
<pub-id pub-id-type="pmid">32494314</pub-id>
</mixed-citation></ref><ref id="ccr39220-bib-0004"><label>4</label><mixed-citation publication-type="miscellaneous" id="ccr39220-cit-0004">
<article-title>Cancer&#x02010;Associated Thrombosis: An Overview of Mechanisms, Risk</article-title>. n.d. Accessed May 29, 2023. <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209883" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209883</ext-link>
</mixed-citation></ref><ref id="ccr39220-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ccr39220-cit-0005">
<string-name>
<surname>D'Elia</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cerruto</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Molinari</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Portal vein thrombosis with renal cell carcinoma: a case report</article-title>. <source>Urol Int</source>. <year>2014</year>;<volume>93</volume>(<issue>2</issue>):<fpage>241</fpage>&#x02010;<lpage>243</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000350649</pub-id>
<pub-id pub-id-type="pmid">23796464</pub-id>
</mixed-citation></ref><ref id="ccr39220-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ccr39220-cit-0006">
<string-name>
<surname>Tabbara</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Gonz&#x000e1;lez</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ciancio</surname>
<given-names>G</given-names>
</string-name>. <article-title>The surgical evolution of radical nephrectomy and tumor thrombectomy: a narrative review</article-title>. <source>Ann Transl Med</source>. <year>2023</year>;<volume>11</volume>(<issue>6</issue>):<fpage>262</fpage>. doi:<pub-id pub-id-type="doi">10.21037/atm-22-2877</pub-id>
<pub-id pub-id-type="pmid">37082681</pub-id>
</mixed-citation></ref></ref-list></back></article>